| Abstract: |
Cardiovascular disease has emerged as the leading cause of death among cancer survivors through the direct effects of cancer on the cardiovascular system and through the toxic effects of chemotherapeutic agents on cardiovascular health. These chemotherapeutic agents cause cardiac dysfunction via several mechanisms including accelerated atherosclerosis, cardiomyopathy, arrhythmias or valvular diseases. To effectively predict and manage cardiovascular complications in cancer survivors, the development of sensitive cardiac biomarkers is essential. The integration of omics, encompassing genomics, epigenomics, transcriptomics, proteomics, miRNAomics, and metabolomics, has significantly advanced the detection of cardiotoxicity through the development of numerous novel biomarkers. The integration of precision medicine and systems biology approaches has revolutionized the field of cardio-oncology, enabling the development of personalized strategies for predicting, preventing, and managing cardiovascular complications in cancer survivors. This chapter explores the application of multiomics and its integration in precision and systems medicine to optimize the prediction and prevention of cardiovascular disease in cancer patients. © 2025 Elsevier Inc. All rights reserved. |
